INKT
MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.87
+1.37%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.99
From 52W high−27.18%
Volume7783.00
Market cap$60.57M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$11.99
From 52W high
−27.18%
Volume
7783.00
Market cap
$60.57M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
P/E (TTM)
—
RSI (14)
52.4
MomentumView details →
1D Return
+1.37%
YTD Return
+4.93%
SummaryUpdated Jun 1, 2026
MiNK Therapeutics, Inc. (NASDAQ:INKT) is a clinical-stage biopharmaceutical company founded in 2017 and based in New York, New York. Originally incorporated as AgenTus Therapeutics, Inc., the company went public in October 2021 and operates as a subsidiary of Agenus Inc. MiNK specializes in developing innovative cancer immunotherapies using a unique type of immune cell called invariant natural killer T (iNKT) cells, positioning itself at the forefront of next-generation cell therapy development.
Similar companies
Latest newsMore news →